

Message

---

**From:** Smith, Brooks M. [Brooks.Smith@troutmansanders.com]  
**Sent:** 3/13/2018 5:37:43 PM  
**To:** Forsgren, Lee [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a055d7329d5b470fbaa9920ce1b68a7d-Forsgren, D]  
**CC:** Penman, Crystal [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=93662678a6fd4d4695c3df22cd95935a-Penman, Crystal]; Campbell, Ann [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b8c25a0c2fb648b6a947694a8492311e-Campbell, Ann]  
**Subject:** RE: Pharma ELG Question

Wonderful – thank you!

**Brooks M. Smith**

troutman sanders

Direct: Ex. 6

brooks.smith@troutman.com

---

**From:** Forsgren, Lee [mailto:Forsgren.Lee@epa.gov]  
**Sent:** Tuesday, March 13, 2018 1:34 PM  
**To:** Smith, Brooks M. <Brooks.Smith@troutmansanders.com>  
**Cc:** Penman, Crystal <Penman.Crystal@epa.gov>; Campbell, Ann <Campbell.Ann@epa.gov>  
**Subject:** RE: Pharma ELG Question

Brooks,

I would be happy to try to find a time to speak with you. Crystal Penman will do her best to find a time that works for all concerned.

Regards,

Lee

**D. Lee Forsgren**

Deputy Assistant Administrator  
Office Of Water  
Environmental Protection Agency  
1200 Pennsylvania Avenue, NW  
Room 3219 WJCE  
Washington, DC 20460  
Phone: 202-564-5700  
[Forsgren.Lee@epa.gov](mailto:Forsgren.Lee@epa.gov)

---

**From:** Smith, Brooks M. [mailto:Brooks.Smith@troutmansanders.com]  
**Sent:** Tuesday, March 13, 2018 12:48 PM  
**To:** Forsgren, Lee <Forsgren.Lee@epa.gov>  
**Subject:** Pharma ELG Question

Greetings Lee, I had the pleasure of seeing you a few times late last year, first at the annual VMA industry environmental conference in Richmond, and then at the NACWA clean water law conference down in Savannah.

I am dealing with an issue for our client, CVS, and I was hoping you might be willing/available to meet and brainstorm potential solutions. The specific issue involves some confusion over the older, existing effluent guidelines for the pharma manufacturing category (40 CFR Part 439), which we think can be resolved with some simple, clarifying guidance. This issue is not in any dispute or litigation – we're just hoping to have some clarification in order to avoid potential conflicts in the future.

Would you be willing to meet? If so, I'd be pleased to coordinate a time and send some background info on the issue. All my best, Brooks

**Brooks M. Smith**

Direct: Ex. 6  
[brooks.smith@troutman.com](mailto:brooks.smith@troutman.com)

**troutman sanders**  
1001 Haxall Point, Suite 1500  
Richmond, VA 23219  
[troutman.com](http://troutman.com)

---

This e-mail message (and any attachments) from Troutman Sanders LLP may contain legally privileged and confidential information solely for the use of the intended recipient. If you received this message in error, please delete the message and notify the sender. Any unauthorized reading, distribution, copying, or other use of this message (and attachments) is strictly prohibited.

---

This e-mail message (and any attachments) from Troutman Sanders LLP may contain legally privileged and confidential information solely for the use of the intended recipient. If you received this message in error, please delete the message and notify the sender. Any unauthorized reading, distribution, copying, or other use of this message (and attachments) is strictly prohibited.